Baseline Blood Indices and Prolonged Length of Hospital Stay

Gulhane Training and Research Hospital

Status: Unknown

Conditions: COVID-19 Pneumonia; Hospitalism; Diabetes Mellitus, Type 2

Treatments: Diagnostic Test: Inflamatory biomarkers

Study type: Observational

Funder types: Other

Identifiers

NCT05054283

2020-374

Details and patient eligibility

About

During a pandemic, length of hospital stay (LOS) is critical to managing high patient volumes and preserves access to care related to non-COVID-19 for maintaining the healthcare system. Moreover, identification of prolonged hospital stay may allow physicians to reevaluate critical patients, focused delivery of specific interventions, and improve the efficiency of hospital care.

Furthermore, in previous recent studies, attention has been paid to patients with diabetes and COVID-19 infection may require a prolonged LOS. However, there is little evidence on prognostic factors associated with an extension of hospitalization in mild or moderate illness due to COVID-19 infection. Therefore, it is crucial to determine the most vulnerable patients with diabetes mellitus even if they have a non-severe COVID-19 infection during the pandemic.

We hypothesize that the clinically relevant inflammatory parameters may have an impact on LOS in older adults with diabetes and non-severe COVID-19 infection. Therefore, we aim to investigate whether baseline inflammatory parameters on admission hospitals as possible predictors of prolonged LOS in older adults with diabetes and non-severe COVID-19 infection during the pandemic.

Enrollment: 90 estimated patients

Sex: All

Ages: 65+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• We included all hospitalized Covid-19 patients with diabetes mellitus according to the any established diagnosis prior to admission or American Diabetes Association guidelines for diagnostic criteria

Exclusion criteria

• The patients with severe Covid-19 infection, secondary diabetes or type 1 diabetes mellitus were excluded.

Trial design

90 participants in 2 patient groups

Length of hospital Stay (normal)

Description:

The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and \> 7 days as prolonged LOS.

Treatment:

Diagnostic Test: Inflamatory biomarkers

Length of hospital Stay (prolonged)

Description:

The primary outcome was hospital length of stay (LOS), which was calculated according to the number of days of hospitalization. Patients were divided into two groups according to median value of LOS: ≤ 7 days as normal and \> 7 days as prolonged LOS.

Treatment:

Diagnostic Test: Inflamatory biomarkers